Login to Your Account



NEW 'INTERNALIZATION STRATEGY'

Yabao inks diabetes deal with Lilly, adds innovative R&D

By Shannon Ellis
Staff Writer

Wednesday, July 9, 2014

SHANGHAI – Yabao Pharmaceutical Co. Inc., of Beijing, has entered a partnership with Eli Lilly and Co. to co-develop Lilly's leading glucokinase activator (GKA), LY2608204, for China's diabetics.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription